PROAIR RESPICLICK
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PROAIR RESPICLICK (PROAIR RESPICLICK).
Selective beta-2 adrenergic receptor agonist; binds to beta-2 receptors on bronchial smooth muscle, activating adenylate cyclase and increasing intracellular cyclic AMP, leading to bronchodilation.
| Metabolism | Primarily metabolized by catechol-O-methyltransferase (COMT) and sulfatase enzymes; minor hepatic metabolism via CYP450 enzymes. |
| Excretion | Primarily renal (60–70% as unchanged drug and metabolites, mainly as 4'-O-sulfate ester); biliary/fecal excretion accounts for <20%. |
| Half-life | Terminal elimination half-life is 3–4 hours for inhaled albuterol; systemic half-life after inhalation is approximately 3.8 hours, supporting q4-6h dosing. |
| Protein binding | Approximately 50–65% bound to plasma proteins (primarily albumin). |
| Volume of Distribution | 1.5–2.5 L/kg (large Vd indicates extensive extravascular distribution, including lung tissue). |
| Bioavailability | Inhalation: 10–20% (systemic absorption from lungs and GI tract following swallowed fraction). |
| Onset of Action | 1–3 minutes via inhalation; peak bronchodilation within 15–30 minutes. |
| Duration of Action | 4–6 hours (dose-dependent); may shorten with prolonged use due to receptor downregulation. |
Two inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed for bronchospasm; for prevention of exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise.
| Dosage form | POWDER, METERED |
| Renal impairment | No dosage adjustment required for renal impairment; pharmacokinetics not significantly altered. |
| Liver impairment | No specific dosage adjustment recommended based on Child-Pugh classification; pharmacokinetics not studied in hepatic impairment. |
| Pediatric use | Children 4 to 11 years: 2 inhalations (180 mcg total) orally inhaled every 4 to 6 hours as needed; for exercise-induced bronchospasm, 2 inhalations 15 to 30 minutes before exercise. |
| Geriatric use | No specific dosage adjustment required; use caution due to potential for increased sensitivity to sympathomimetic effects; monitor for adverse effects such as tremor, tachycardia, or elevated blood pressure. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PROAIR RESPICLICK (PROAIR RESPICLICK).
| Breastfeeding | Albuterol is excreted into human milk in small amounts (M/P ratio not established). Estimated infant dose <1% of maternal weight-adjusted dose. No published adverse effects. Use with caution, especially in preterm infants. Monitor infant for signs of sympathetic stimulation (tachycardia, irritability). |
| Teratogenic Risk | Pregnancy Category C. In animal studies, albuterol administered subcutaneously at doses 0.5-50 times the maximum recommended human inhalation dose (MRHID) caused cleft palate, delayed ossification, and decreased fetal weight. No adequate and well-controlled studies in pregnant women. Use only if potential benefit justifies risk. First trimester: Risk cannot be ruled out. Second and third trimesters: Risk of maternal tachycardia, hypoglycemia, and hypokalemia; preterm labor inhibition may occur; avoid use during labor due to risk of transient fetal hypoglycemia. |
■ FDA Black Box Warning
None
| Serious Effects |
["Hypersensitivity to albuterol or any ingredient in the formulation"]
| Precautions | ["Paradoxical bronchospasm may occur, which can be life-threatening","Cardiovascular effects: increased heart rate, blood pressure, or ECG changes; use caution in patients with cardiovascular disorders","Fatalities reported with excessive use","Immediate hypersensitivity reactions (urticaria, angioedema, rash)","Do not exceed recommended dose; excessive use may lead to death","Hypokalemia and hyperglycemia may occur, especially with high doses"] |
Loading safety data…
| Fetal Monitoring | Monitor maternal heart rate, blood pressure, serum potassium, and blood glucose. In pregnancy, monitor fetal heart rate and uterine activity during acute exacerbations. Consider fetal ultrasound to rule out congenital anomalies if exposure occurs during first trimester. |
| Fertility Effects | No formal fertility studies in humans. In animal studies, albuterol caused decreased fertility and reduced conception rates in rats at high doses (50 times MRHID). Clinical significance unknown. |